GENSCRIPT-BIOTECH
14.4.2021 07:32:13 CEST | Business Wire | Press release
GenScript Biotech (Netherlands) BV , a subsidiary of GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.
The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently received clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.
"With this collaboration, IES Diagnostics and GenScript will join forces to serve the local community with our expertise and resources. Since the outbreak of the worldwide pandemic in 2020, our company has been committed to supporting the global community in fighting COVID-19 with a comprehensive portfolio to support therapeutics and vaccine research and development, and diagnostic tool development including the novel cPass kit," said Aaron Qian, the President of European Division of GenScript.
Hubert Thomassen, CEO of IES Medical, said, "We are honored to be working with GenScript, proud to provide the unique and highly innovative cPass kit to our society that will contribute decisively to the knowledge of the immune status and level of protection of both those who have suffered a SARS-CoV-2 infection and those citizens who have been or will be vaccinated. The cPass kit is an essential tool in the development of any therapy aimed at combating this pandemic and in the development of an international immunity passport that allows our society to resume a normal social and economic life."
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform. The company’s operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. GenScript provides premium, convenient, and reliable products, and services for over 100,000 customers.
For more information visit http://www.genscript.com .
About IES Diagnostics
IES Diagnostics is the LifeScience division of IES Medical. IES Medical has its headquarters in Bilbao and offices in Madrid and Barcelona. The company directly serves clients all over the Iberian peninsula. IES Medical has a long-standing reputation for providing innovative products that contribute to improving the health of society in the areas of Emergency Medicine, Woundcare, Respiratory, and Diagnostics. The overall objective of IES Medical is to provide innovation for better care,
For more information visit https://www.iesmedical.es/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Former SADA Executive Lusine Yeghiazaryan Joins Picsart as CFO to Drive AI-Native Video Growth Strategy3.9.2026 14:00:00 CEST | Press release
Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903569581/en/ Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. Yeghiazaryan joins Picsart at a pivotal chapter in its evolution, as the company expands beyond its roots as a leading creative platform to build a video-first, AI-powered production ecosystem. Already in motion, Picsart users created over 1.1B AI videos and images since launch, with YTD AI usage up 270% year over year - underscoring the company’s accelerating push to capture a larger share of the fast-growing AI content m
Hitachi Expands HMAX to Accelerate the Deployment of Physical AI3.9.2026 14:00:00 CEST | Press release
New solutions for data centers, cybersecurity, and operational knowledge digitalization enable intelligent digital infrastructure Hitachi, Ltd. ("Hitachi") today announced the expansion of HMAX by Hitachi ("HMAX")*, a next-generation suite of solutions that brings the power of AI to social infrastructure. The HMAX portfolio consists of Domain-Specific Solutions tailored to industries and business operations, as well as a set of foundry solutions that span across domains. As part of this expansion, HMAX Data Center has been added as a Domain-Specific Solution for data center operators. Additionally, HMAX Cyber, HMAX Data Fabric, and HMAX AI Operations are being introduced as foundry solutions that support not only Physical AI initiatives within HMAX but also integrate and support enterprises' existing systems across different domains and environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046122/en/ HMAX Soluti
NetApp and AWS Accelerate Storage Migrations with AWS Transform3.9.2026 14:00:00 CEST | Press release
Enterprises can now migrate attached storage and database workloads directly to Amazon FSx for NetApp ONTAP with AWS Transform NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Amazon Web Services (AWS) today announced that AWS Transform now supports Amazon FSx for NetApp ONTAP, making it even easier for enterprises to move applications and data to AWS. AWS Transform is an agentic AI service that automates the discovery, planning, and migration of workloads to the cloud. Now generally available, customers can use AWS Transform to migrate attached storage from their on-premises and cloud estates directly to Amazon FSx for ONTAP. “Cloud migration projects often take longer and cost more than expected because customers have to move applications, servers, networking, and storage separately,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage and Services at NetApp. “With AWS Transform and Amazon FSx for NetApp ONTAP, customers can simplify
MultiBank Group Named Most Regulated Global Financial Derivatives Institution.3.9.2026 13:47:00 CEST | Press release
MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046526/en/ MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. The award highlights MultiBank Group’s strong global regulatory framework as it holds more than 18 regulatory licences across five continents, including the Australian Securities and Investments Commission (ASIC), the German Federal Financial Supervisory Authority (BaFin), the Cyprus Securities and Exchange Commission (CySEC), the UAE’s Capital Market Authority (CMA), reflecting its longstanding commitment to governance, compliance and transparency. The latest recognition adds to MultiBank Group’s growing award portfolio of more than 80 international industry awards, spanning areas including financial services, trading technology, reg
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 12:07:00 CEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom